Company Overview

Conavi Medical Corp. is a Canada-based medical technology company focused on the development and commercialization of intravascular imaging solutions for the diagnosis and management of cardiovascular disease. The company operates within the medical devices and cardiovascular imaging industries, with a specific emphasis on catheter-based imaging technologies used during coronary and peripheral vascular interventions.

Conavi’s primary products and revenue drivers are its proprietary intravascular imaging platforms, which are designed to provide high-resolution visualization of blood vessels to support clinical decision-making. The company’s technology integrates optical coherence tomography (OCT) with catheter-based delivery systems, positioning Conavi as a specialized provider in a niche segment of interventional cardiology. Founded in Canada, Conavi has evolved from a research-driven enterprise into a publicly traded company listed on the TSX Venture Exchange, with regulatory clearances supporting commercialization in select markets.

Business Operations

Conavi Medical operates primarily through the development, manufacturing, and commercialization of its intravascular imaging systems, with its core business centered on the NOVASIGHT Hybrid™ System and related catheter products. Revenue generation is driven by system sales, disposable imaging catheters, and clinical adoption within hospital catheterization laboratories. The company’s operations are structured around research and development, regulatory affairs, and limited commercial distribution.

The company conducts operations in both domestic and international markets, with technology development and corporate functions based in Canada and commercial activities extending into the United States and other regulated healthcare markets. Conavi maintains control over its proprietary imaging technology and intellectual property, while leveraging third-party manufacturing and distribution relationships. Public disclosures indicate no large-scale joint ventures, but the company has engaged in strategic clinical and commercialization partnerships to support market entry and adoption.

Strategic Position & Investments

Conavi’s strategic direction centers on expanding clinical adoption of its intravascular imaging technology and advancing next-generation imaging platforms. Growth initiatives include broadening regulatory approvals, increasing physician awareness, and expanding indications for use in coronary and peripheral artery disease. The company has also emphasized continued investment in research and development to enhance image quality, workflow integration, and hybrid imaging capabilities.

The company has pursued selective investments in product development rather than large-scale acquisitions, reflecting its focus on organic growth. Its strategic positioning is differentiated by the hybrid integration of OCT with angiographic guidance, which is intended to reduce procedural complexity and improve imaging precision. Emerging areas of focus include enhanced data visualization and potential future integration with advanced analytics, though commercialization timelines for such technologies are not fully disclosed in public filings.

Geographic Footprint

Conavi Medical Corp. is headquartered in Toronto, Ontario, Canada, which serves as the center for its executive leadership, research, and corporate operations. The company maintains a market presence in North America, with a primary commercial focus on the United States, where interventional cardiology represents a significant addressable market.

Internationally, Conavi has pursued regulatory clearances and limited commercial penetration in select regions outside North America. Its global footprint remains relatively concentrated, reflecting its size and stage of commercialization, but the company has indicated an intent to expand international distribution through partnerships and regulatory approvals in additional jurisdictions.

Leadership & Governance

Conavi Medical is led by an executive team with experience in medical devices, cardiovascular technologies, and public company governance. The leadership emphasizes innovation, regulatory rigor, and disciplined capital deployment as core elements of its strategic vision.

Key executives include:

• Ajit Singh – Chief Executive Officer
• Thomas Looby – Chief Financial Officer
• Dr. Mauro Carlone – Founder and Chief Technology Officer
• Barry McLean – Vice President, Clinical & Regulatory Affairs

The company is governed by a board of directors that provides oversight on strategy, risk management, and shareholder interests, consistent with Canadian public company governance standards.